Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

By LabMedica International staff writers
Posted on 09 May 2025

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance. More...

AATD is a genetic disorder where the body does not produce sufficient amounts of a protective protein, whereas COPD is typically the result of prolonged exposure to irritants such as cigarette smoke. AATD is the second most common genetic lung disease in the United States, following cystic fibrosis. Affecting roughly 1 in 3,000 to 1 in 5,000 individuals, it is estimated to impact about 100,000 Americans, although many cases remain undiagnosed, leading to delayed treatment and potentially worse outcomes. Researchers have now developed a groundbreaking molecular diagnostic test that can accurately diagnose AATD, addressing a long-standing challenge in the medical community.

The innovative 23-SNP alpha-1 antitrypsin (AAT) assay, developed by scientists at National Jewish Health (Denver, CO, USA), significantly enhances the speed and accuracy of diagnosing AATD by identifying multiple genetic mutations linked to the condition. In a study published in CHEST Pulmonary, the researchers validated the assay using 373 biological samples, demonstrating its capability to detect 20 pathogenic mutations in the SERPINA1 gene, which is responsible for producing AAT protein, as well as two normal variants and an additional variant that is still being studied.

This new assay expands the number of genotypes that can be detected, including rare alleles such as F, I, and some null alleles. The results showed 100% accuracy in identifying abnormal mutations in patients with AATD, greatly surpassing the traditional isoelectric focusing gel method and other molecular tests that only detect S and Z alleles. The researchers believe this test could serve as a foundation for newborn screening programs and at-home sample collection, offering a significant boost to early detection efforts.

“AATD is widely underdiagnosed, leading to delays in treatment that can worsen disease outcomes,” said Yongbao Wang, PhD, lead researcher and senior author on the paper. “Our test provides an accurate, comprehensive and rapid genotyping solution that can be implemented as a frontline diagnostic tool.”

“This is a significant step forward for both clinicians and patients,” added Sharon Kuss-Duerkop, PhD, senior scientist at National Jewish Health. “With quicker and more reliable results, we can diagnose AATD earlier and start appropriate treatments, potentially preventing severe lung and liver complications.”

Related Links:
National Jewish Health


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.